2,2,4-三甲基-6-苯基-1H-喹啉 | 3562-69-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2,2,4-三甲基-6-苯基-1H-喹啉
• 英文名称: LG001447
• 英文别名: 2,2,4-trimethyl-6-phenyl-1,2-dihydro-quinoline；2,2,4-Trimethyl-6-phenyl-1,2-dihydro-chinolin；1,2-dihydro-2,2,4-trimethyl-6-phenylquinoline；2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline；2,2,4-trimethyl-6-phenyl-1H-quinoline
• CAS: 3562-69-4
• 化学式: C₁₈H₁₉N
• 分子量: 249.356
• InChiKey: XKBGEVHKVFIMLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  2,2,4-三甲基-6-苯基-1H-喹啉 在 N-溴代丁二酰亚胺(NBS) 、 potassium carbonate 作用下， 以 二甲基亚砜 、 乙腈 为溶剂， 反应 16.5h， 生成 4-allylsulfanylmethyl-2,2-dimethyl-6-phenyl-1,2-dihydroquinoline
  参考文献：
  名称：

  Discovery and SAR study of novel dihydroquinoline containing glucocorticoid receptor ligands

  摘要：

  We report the discovery of a novel class of glucocorticoid receptor (GR) ligands based on 1,2-dihydroquinoline molecular scaffold. The compounds exhibit good GR binding affinity and selectivity profile against other nuclear hormone receptors. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.043
• 作为产物：
  描述：

  4-氨基联苯 以 N-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine 为溶剂， 以61%的产率得到2,2,4-三甲基-6-苯基-1H-喹啉
  参考文献：
  名称：

  Compounds for the treatment of pain

  摘要：

  这项发明提供了治疗疼痛、尿失禁和其他由NPFF受体介导的异常的方法，包括向受试者施用在NPFF1受体、NPFF2受体或同时在NPFF1和NPFF2受体上起作用的化学化合物的治疗有效量。

  公开号：

  US20030176314A1

文献信息

• Steroid receptor modulator compounds and methods
  申请人：Ligand Pharmaceuticals Incorporated

  公开号：US05696127A1

  公开（公告）日：1997-12-09

  Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

  披露了对类固醇受体具有高亲和力、高选择性调节剂的非类固醇化合物。还披露了包含这些化合物的药物组合物、使用所披露的化合物和组合物治疗需要类固醇受体激动剂或拮抗剂治疗的患者的方法，以及在制备这些化合物中有用的中间体和制备类固醇受体调节剂化合物的过程。
• Tricyclic steroid receptor modulator compounds and methods
  申请人：Ligand Pharmaceuticals Incorporated

  公开号：US05696130A1

  公开（公告）日：1997-12-09

  Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

  披露了对类固醇受体具有高亲和力、高选择性调节剂的非类固醇化合物。还披露了包含这些化合物的药物组合物、使用所披露的化合物和组合物治疗需要类固醇受体激动剂或拮抗剂治疗的患者的方法，以及在制备这些化合物中有用的中间体和制备类固醇受体调节剂化合物的过程。
• Olefin polymerization catalyst system and process for use thereof
  申请人：Rix C. Francis

  公开号：US20060009595A1

  公开（公告）日：2006-01-12

  This invention relates to a compound represented by the formula: where M is a transition metal selected from group 4 of the periodic table; each R 1 is independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl and functional group, and any two R 1 may be linked, provided that if the two R 1 groups are linked, then they do not form a butadiene group when M is Zr; each R 2 is independently selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl and the isomers thereof, provided that when R 3 and R 6 and or R 12 and R 15 form a 5 carbon ring, then each R 2 is independently selected from the group consisting of ethyl, propyl, butyl, pentyl, hexyl and the isomers thereof; R 3 is carbon or silicon; R 4 is hydrogen, hydrocarbyl, substituted hydrocarbyl or a functional group; a is 0, 1, or 2; R 5 is hydrogen, hydrocarbyl, substituted hydrocarbyl or a functional group, R 4 and R 5 may be bound together to form a ring, and R 5 and R 3 may be bound together to form a ring; b is 0, 1, or 2; R 6 is carbon or silicon; and R 4 and R 6 may be bound together to form a ring; each R 7 is hydrogen; each R 8 is independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl and the isomers thereof; each R 9 is independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl and a functional group, and two R 9 groups may be linked together to form a ring, R 9 and R 8 may be linked together to form a ring, R 9 and R 16 may be linked together to form a ring, R 9 and R 11 may be linked together to form a ring; c is 0, 1 or 2; R 10 is -M 2 (R 16 ) h — where M 2 is B, Al, N, P, Si or Ge, h is an integer from 1 to 2 , such that the valence of M 2 is filled, and R 16 is hydrogen, hydrocarbyl, substituted hydrocarbyl or a functional group, and two R 16 groups may be linked together to form a ring; d is 0, 1, or 2; each R 11 is independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl and a functional group, and two R 11 groups may be linked together to form a ring. R 11 and R 8 may be linked together to form a ring. R 11 and R 16 may be linked together to form a ring; e is 0, 1, or 2; where the sum of c, d, and e is 1, 2 or 3; R 12 is carbon or silicon; R 13 is hydrogen, hydrocarbyl, substituted hydrocarbyl or a functional group, and R 13 and R 14 may be bound together to form a ring, and R 13 and R 15 may be bound together to form a ring, when g is 0; f is 0, 1, or 2; R 14 is hydrogen, hydrocarbyl, substituted hydrocarbyl or a functional group, and R 14 and R 12 may be bound together to form a ring, when f is 0; g is 0, 1, or 2; and R 15 is carbon or silicon. This invention further relates to a process to polymerize unsaturated monomers using the above compositions.

  本发明涉及一种由以下公式表示的化合物：其中M是周期表中4族过渡金属中选取的元素；每个R1独立地选自氢、烃基、取代烃基和官能团组成的群体，任意两个R1可能被连接，前提是如果两个R1组被连接，则当M为Zr时它们不形成丁二烯基团；每个R2独立地选自甲基、乙基、丙基、丁基、戊基、己基及其异构体组成的群体，前提是当R3和R6以及/或R12和R15形成一个5碳环时，每个R2独立地选自乙基、丙基、丁基、戊基、己基及其异构体；R3是碳或硅；R4是氢、烃基、取代烃基或官能团；a为0、1或2；R5是氢、烃基、取代烃基或官能团，R4和R5可能结合形成一个环，R5和R3可能结合形成一个环；b为0、1或2；R6是碳或硅；R4和R6可能结合形成一个环；每个R7是氢；每个R8独立地选自氢、甲基、乙基、丙基、丁基、戊基、己基及其异构体；每个R9独立地选自氢、烃基、取代烃基和官能团组成的群体，两个R9组可能连接以形成一个环，R9和R8可能连接以形成一个环，R9和R16可能连接以形成一个环，R9和R11可能连接以形成一个环；c为0、1或2；R10是-M2(R16)h—，其中M2是B、Al、N、P、Si或Ge，h是1到2之间的整数，使得M2的价被填满，R16是氢、烃基、取代烃基或官能团，两个R16组可能连接以形成一个环；d为0、1或2；每个R11独立地选自氢、烃基、取代烃基和官能团组成的群体，两个R11组可能连接以形成一个环。R11和R8可能连接以形成一个环。R11和R16可能连接以形成一个环；e为0、1或2；其中c、d和e的总和为1、2或3；R12是碳或硅；R13是氢、烃基、取代烃基或官能团，当g为0时，R13和R14可能结合形成一个环，R13和R15可能结合形成一个环；f为0、1或2；R14是氢、烃基、取代烃基或官能团，当f为0时，R14和R12可能结合形成一个环；g为0、1或2；R15是碳或硅。此外，本发明还涉及使用上述组合物聚合不饱和单体的方法。
• Novel facile synthesis of 2,2,4 substituted 1,2-dihydroquinolines via a modified Skraup reaction
  作者：Maria-Elena Theoclitou、Leslie A. Robinson

  DOI：10.1016/s0040-4039(02)00614-7

  日期：2002.5

  A variety of 2,2,4 substituted 1,2-dihydroquinolines were synthesized from substituted anilines or aminoheterocycles and the corresponding ketones in good yield via the use of lanthanide catalysts and microwave technology. This method can be readily applied to the general synthesis of combinatorial libraries of dihydroquinolines.

  通过使用镧系元素催化剂和微波技术，由取代的苯胺或氨基杂环以及相应的酮以高收率合成了各种2,2,4个取代的1,2-二氢喹啉。该方法可以容易地应用于二氢喹啉组合库的一般合成。
• Discovery and Preliminary SAR Studies of a Novel, Nonsteroidal Progesterone Receptor Antagonist Pharmacophore
  作者：Charlotte L. F. Pooley、James P. Edwards、Mark E. Goldman、Ming-Wei Wang、Keith B. Marschke、Diane L. Crombie、Todd K. Jones

  DOI：10.1021/jm9801915

  日期：1998.8.1

  A series of 6-aryl-1,2-dihydro-2,2,4-trimethylquinolines was synthesized and tested for functional activity on the human progesterone receptor isoform B (hPR-B) in mammalian (CV-1) cells. The lead compound LG001447 (1,2-dihydro-2,2, 4-trimethyl-6-phenylquinoline) was discovered via directed high throughput screening of a defined chemical library utilizing an hPR-B cotransfection assay. Electron-withdrawing

  合成了一系列的6-芳基-1,2-二氢-2,2,4-三甲基喹啉，并测试了其在哺乳动物（CV-1）细胞中对人孕激素受体同工型B（hPR-B）的功能活性。通过使用hPR-B共转染法对定义的化学文库进行定向高通量筛选，发现了铅化合物LG001447（1,2-二氢-2,2,4-三甲基-6-苯基喹啉）。C（6）芳基的间位上的吸电子取代基提供了hPR调节活性的实质性改进。几种类似物能够在体外有效阻断孕激素的作用。两种化合物，即效力与类固醇hPR拮抗剂onapristone（ZK98,299）相当或相等的化合物10（LG120753）和11（LG120830）在口服给啮齿动物后，在体内起着抗孕激素的作用。